Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Change in Account Payables (2023 - 2025)

Historic Change in Account Payables for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $1.2 million.

  • CG Oncology's Change in Account Payables rose 39566.27% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.3 million, marking a year-over-year increase of 9296.03%. This contributed to the annual value of $3.3 million for FY2024, which is 6277.34% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Change in Account Payables is $1.2 million, which was up 39566.27% from $394000.0 recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Change in Account Payables registered a high of $2.4 million during Q4 2024, and its lowest value of -$415000.0 during Q3 2024.
  • Its 3-year average for Change in Account Payables is $647454.5, with a median of $394000.0 in 2025.
  • Data for CG Oncology's Change in Account Payables shows a peak YoY increase of 1584444.44% (in 2024) and a maximum YoY decrease of 44285.71% (in 2024) over the last 5 years.
  • Quarter analysis of 3 years shows CG Oncology's Change in Account Payables stood at $1.4 million in 2023, then soared by 76.63% to $2.4 million in 2024, then crashed by 49.73% to $1.2 million in 2025.
  • Its Change in Account Payables was $1.2 million in Q3 2025, compared to $394000.0 in Q2 2025 and $214000.0 in Q1 2025.